Sign in
CTNM Stock Price, Chart, Stats & News
Contineum Therapeutics, Inc. Class A Common Stock
Save
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) does not currently pay a dividend.
519.67M
Market cap
–
Current P/E
–
Forward P/E
CTNM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.68% |
ROE | -30.08% |
D/E | 0.03x |
Interest coverage ratio | – |
CTNM valuation
P/E | – |
P/S | – |
P/B | 1.58x |
P/CF | -7.44x |
P/FCF | -8.97x |
P/OCF | -7.44x |
PEG | -1.00x |
EV multiple | -8.87x |
About
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
Similar securities
Based on sector and market capitalization
Report issue